Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) motto: Worried about in 2018 (?), think five (5) things …

February 6, 2018 2:55pm

Cash positions … WHO needs to “tap” the capital markets for continued survival? How are enrollments going as to population and are they sustainable re drop-outs? Has the data from on-going trials been construed as to render measureable and definitive outcomes? Is the company partnered to ward-off the issues of dilution and share depreciation! And finally, does the current CEO have the staying power to withstand their past mistakes and take our investments to the next stage – 2018?

Learn who is stumbling and what the mumbling means …

For 8 years, RMi is the only source of actionable intelligence for the stem, cell and gene therapy and regenerative medicine’s universe (SCGT&RM).

You’ve enjoyed complimentary access to unbiased analysis, in-depth analytics, and informational synthesis along with RMi’s exclusive listing of “our” universe’s stocks and their potential for gains and losses; but exclusivity is now here. Access to RegMed Investors’ targeted content will be by subscription only.

For continued access to what one industry CEO calls the “Bible” for smart investing in the RegMed and cell therapy sector, click on the button below:

http://www.regmedinvestors.com/create-account

..... Never leave an investor uninformed .......

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

9 hours 22 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.